vs
Side-by-side financial comparison of Day One Biopharmaceuticals, Inc. (DAWN) and FRANKLIN COVEY CO (FC). Click either name above to swap in a different company.
FRANKLIN COVEY CO is the larger business by last-quarter revenue ($64.0M vs $39.8M, roughly 1.6× Day One Biopharmaceuticals, Inc.). FRANKLIN COVEY CO runs the higher net margin — -5.1% vs -49.6%, a 44.4% gap on every dollar of revenue. On growth, FRANKLIN COVEY CO posted the faster year-over-year revenue change (-7.3% vs -57.6%).
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing targeted precision oncology therapies for pediatric and young adult patients with genetically driven cancers. It advances novel drug candidates to address unmet medical needs in underserved patient segments, operating primarily in the U.S. and partnering with global oncology research institutions.
Franklin Covey Co., trading as FranklinCovey and based in Salt Lake City, Utah, is a coaching company which provides training and assessment services in the areas of leadership, individual effectiveness, and business execution for organizations and individuals. The company was formed on May 30, 1997, as a result of merger between Hyrum W. Smith's Franklin Quest and Stephen R. Covey's Covey Leadership Center. Among other products, the company has marketed the FranklinCovey planning system, mod...
DAWN vs FC — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $39.8M | $64.0M |
| Net Profit | $-19.7M | $-3.3M |
| Gross Margin | — | 75.5% |
| Operating Margin | -60.9% | -5.7% |
| Net Margin | -49.6% | -5.1% |
| Revenue YoY | -57.6% | -7.3% |
| Net Profit YoY | -153.3% | -378.5% |
| EPS (diluted) | $-0.19 | $-0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $64.0M | ||
| Q3 25 | $39.8M | $71.2M | ||
| Q2 25 | $33.9M | $67.1M | ||
| Q1 25 | $30.8M | $59.6M | ||
| Q4 24 | — | $69.1M | ||
| Q3 24 | $93.8M | $84.1M | ||
| Q2 24 | — | $73.4M | ||
| Q1 24 | $0 | $61.3M |
| Q4 25 | — | $-3.3M | ||
| Q3 25 | $-19.7M | $4.4M | ||
| Q2 25 | $-30.3M | $-1.4M | ||
| Q1 25 | $-36.0M | $-1.1M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | $37.0M | $12.0M | ||
| Q2 24 | — | $5.7M | ||
| Q1 24 | $-62.4M | $874.0K |
| Q4 25 | — | 75.5% | ||
| Q3 25 | — | 75.5% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 76.7% | ||
| Q4 24 | — | 76.3% | ||
| Q3 24 | — | 78.1% | ||
| Q2 24 | — | 76.6% | ||
| Q1 24 | — | 76.4% |
| Q4 25 | — | -5.7% | ||
| Q3 25 | -60.9% | 11.1% | ||
| Q2 25 | -103.1% | -3.3% | ||
| Q1 25 | -133.5% | -2.4% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | 31.6% | 21.3% | ||
| Q2 24 | — | 11.4% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | -5.1% | ||
| Q3 25 | -49.6% | 6.1% | ||
| Q2 25 | -89.4% | -2.1% | ||
| Q1 25 | -117.0% | -1.8% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | 39.5% | 14.2% | ||
| Q2 24 | — | 7.8% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | — | $-0.27 | ||
| Q3 25 | $-0.19 | $0.34 | ||
| Q2 25 | $-0.29 | $-0.11 | ||
| Q1 25 | $-0.35 | $-0.08 | ||
| Q4 24 | — | $0.09 | ||
| Q3 24 | $0.38 | $0.89 | ||
| Q2 24 | — | $0.43 | ||
| Q1 24 | $-0.72 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $451.6M | $17.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $450.9M | $54.0M |
| Total Assets | $513.8M | $221.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $17.5M | ||
| Q3 25 | $451.6M | $31.7M | ||
| Q2 25 | $453.1M | $33.7M | ||
| Q1 25 | $473.0M | $40.4M | ||
| Q4 24 | — | $53.3M | ||
| Q3 24 | $558.4M | $48.7M | ||
| Q2 24 | — | $36.6M | ||
| Q1 24 | $317.9M | $40.9M |
| Q4 25 | — | $54.0M | ||
| Q3 25 | $450.9M | $66.9M | ||
| Q2 25 | $460.8M | $65.6M | ||
| Q1 25 | $479.5M | $72.5M | ||
| Q4 24 | — | $80.6M | ||
| Q3 24 | $555.5M | $83.1M | ||
| Q2 24 | — | $72.2M | ||
| Q1 24 | $296.8M | $70.8M |
| Q4 25 | — | $221.3M | ||
| Q3 25 | $513.8M | $242.9M | ||
| Q2 25 | $519.0M | $218.3M | ||
| Q1 25 | $534.4M | $221.3M | ||
| Q4 24 | — | $239.9M | ||
| Q3 24 | $600.8M | $261.5M | ||
| Q2 24 | — | $221.0M | ||
| Q1 24 | $326.6M | $221.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.8M | $98.0K |
| Free Cash FlowOCF − Capex | — | $-1.6M |
| FCF MarginFCF / Revenue | — | -2.5% |
| Capex IntensityCapex / Revenue | 0.0% | 2.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $98.0K | ||
| Q3 25 | $-5.8M | $9.9M | ||
| Q2 25 | $-24.8M | $6.3M | ||
| Q1 25 | $-59.0M | $-1.4M | ||
| Q4 24 | — | $14.1M | ||
| Q3 24 | $50.8M | $21.9M | ||
| Q2 24 | — | $8.2M | ||
| Q1 24 | $-49.7M | $12.8M |
| Q4 25 | — | $-1.6M | ||
| Q3 25 | — | $5.7M | ||
| Q2 25 | $-24.8M | $4.5M | ||
| Q1 25 | $-59.3M | $-2.6M | ||
| Q4 24 | — | $13.1M | ||
| Q3 24 | $50.0M | $20.8M | ||
| Q2 24 | — | $7.3M | ||
| Q1 24 | — | $12.1M |
| Q4 25 | — | -2.5% | ||
| Q3 25 | — | 8.0% | ||
| Q2 25 | -73.2% | 6.7% | ||
| Q1 25 | -192.8% | -4.4% | ||
| Q4 24 | — | 19.0% | ||
| Q3 24 | 53.4% | 24.7% | ||
| Q2 24 | — | 9.9% | ||
| Q1 24 | — | 19.8% |
| Q4 25 | — | 2.7% | ||
| Q3 25 | 0.0% | 5.9% | ||
| Q2 25 | 0.0% | 2.7% | ||
| Q1 25 | 1.0% | 2.1% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.27× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 11.98× | ||
| Q3 24 | 1.37× | 1.83× | ||
| Q2 24 | — | 1.43× | ||
| Q1 24 | — | 14.62× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
FC
Segment breakdown not available.
